Edwin DeJesus1, Moti Ramgopal2, Gordon Crofoot3, Peter Ruane4, Anthony LaMarca5, Anthony Mills6, Claudia T Martorell7, Joseph de Wet8, Hans-Jürgen Stellbrink9, Jean-Michel Molina10, Frank A Post11, Ignacio Pérez Valero12, Danielle Porter13, YaPei Liu13, Andrew Cheng13, Erin Quirk13, Devi SenGupta13, Huyen Cao14. 1. Orlando Immunology Center, Orlando, FL, USA. 2. Midway Immunology and Research Center, Fort Pierce, FL, USA. 3. The Crofoot Research Center, Houston, TX, USA. 4. Ruane Medical, Los Angeles, CA, USA. 5. Therafirst Medical Center, Fort Lauderdale, FL, USA. 6. Southern California Men's Medical Group, Los Angeles, CA, USA. 7. The Research Institute, Springfield, MA, USA. 8. Spectrum Health Care, Vancouver, BC, Canada. 9. ICH Study Center, Hamburg, Denmark. 10. Hopital Saint Louis, Paris, France. 11. Kings College Hospital, London, UK. 12. Hospital Universitario La Paz, Madrid, Spain. 13. Gilead Sciences, Foster City, CA, USA. 14. Gilead Sciences, Foster City, CA, USA. Electronic address: huyen.cao@gilead.com.
Abstract
BACKGROUND:Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate. METHODS: In this randomised, double-blind, placebo-controlled, non-inferiority trial, HIV-1-infected adults were enrolled at 120 hospitals and outpatient clinics in eight countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min. Participants were randomly assigned (1:1) to receive a single-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo. Investigators, participants, study staff, and those assessing outcomes were masked to treatment group. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of less than 50 copies per mL at week 48 (assessed by the US Food and Drug Administration snapshot algorithm), with a prespecified non-inferiority margin of 8%. This study was registered with ClinicalTrials.gov, number NCT02345226. FINDINGS:Between Jan 26, 2015, and Aug 27, 2015, 875 participants were randomly assigned and treated (438 withrilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate). Viral suppression at week 48 was maintained in 394 (90%) of 438 participants assigned to thetenofovir alafenamide regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2·0%, 95·001% CI -5·9 to 1·8), demonstrating non-inferiority. 56 (13%) of 438 in participants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienced treatment-related adverse events compared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group. INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppression and was well tolerated at 48 weeks. These findings support guidelines recommending tenofovir alafenamide-based regimens, including coformulation with rilpivirine and emtricitabine, as initial and ongoing treatment for HIV-1 infection. FUNDING: Gilead Sciences.
RCT Entities:
BACKGROUND:Tenofovir alafenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks. The coformulation of rilpivirine, emtricitabine, and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safety, and tolerability of switching to this regimen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumarate. METHODS: In this randomised, double-blind, placebo-controlled, non-inferiority trial, HIV-1-infected adults were enrolled at 120 hospitals and outpatient clinics in eight countries in North America and Europe. Participants were virally suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL/min. Participants were randomly assigned (1:1) to receive a single-tablet regimen of rilpivirine (25 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo. Investigators, participants, study staff, and those assessing outcomes were masked to treatment group. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of less than 50 copies per mL at week 48 (assessed by the US Food and Drug Administration snapshot algorithm), with a prespecified non-inferiority margin of 8%. This study was registered with ClinicalTrials.gov, number NCT02345226. FINDINGS: Between Jan 26, 2015, and Aug 27, 2015, 875 participants were randomly assigned and treated (438 with rilpivirine, emtricitabine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate). Viral suppression at week 48 was maintained in 394 (90%) of 438 participants assigned to the tenofovir alafenamide regimen and 402 (92%) of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2·0%, 95·001% CI -5·9 to 1·8), demonstrating non-inferiority. 56 (13%) of 438 in participants in the rilpivirine, emtricitabine, and tenofovir alafenamide group experienced treatment-related adverse events compared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumarate group. INTERPRETATION: Switching to rilpivirine, emtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppression and was well tolerated at 48 weeks. These findings support guidelines recommending tenofovir alafenamide-based regimens, including coformulation with rilpivirine and emtricitabine, as initial and ongoing treatment for HIV-1 infection. FUNDING: Gilead Sciences.
Authors: Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; David A Wohl; Claire E Farel; Joseph J Eron Journal: AIDS Date: 2019-06-01 Impact factor: 4.177
Authors: Grace A McComsey; Sergio Lupo; David Parks; Mónica Coronado Poggio; Joseph De Wet; Lesley P Kahl; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Martin Gartland; Michael Cupo; Michael Aboud Journal: AIDS Date: 2018-02-20 Impact factor: 4.177
Authors: Joseph J Eron; Chloe Orkin; Joel Gallant; Jean-Michel Molina; Eugenia Negredo; Andrea Antinori; Anthony Mills; Jacques Reynes; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; John Jezorwski; Simon Vanveggel; Magda Opsomer Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Pedro E Ferrer; Mark Bloch; Norman Roth; Robert Finlayson; David Baker; Ken Koh; David Orth; Rimgaile Urbaityte; Dannae Brown; Fraser Drummond Journal: Int J STD AIDS Date: 2017-09-13 Impact factor: 1.359